Načítá se...
Protease inhibitors for the treatment of hepatitis C virus infection
The hepatitis C virus (HCV) has affected an estimate of 80 million individuals worldwide and is a strain of public health. Around 25–30% of patients in Europe and the US infected with HIV are coinfected with HCV. Despite treatment modalities containing a NS3/4A protease inhibitor in combination with...
Uloženo v:
| Vydáno v: | GMS Infect Dis |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
German Medical Science GMS Publishing House
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6301719/ https://ncbi.nlm.nih.gov/pubmed/30671330 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3205/id000034 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|